This bill amends the definition of "interchangeable biological product" and establishes guidelines for pharmacists regarding the substitution of biological products. It introduces new definitions for "biosimilar" and "interchangeable biological product," specifying that an interchangeable biological product must meet the criteria set forth in federal law, particularly under 42 U.S.C. section 262(i)(3). The bill also mandates that pharmacists can only substitute a biological product for the prescribed one if it meets the definition of an interchangeable biological product. Additionally, it requires pharmacists to inform patients when an interchangeable product is dispensed and to document the specific product provided, ensuring that this information is accessible to the prescriber.

Key provisions include the stipulation that pharmacists cannot substitute an interchangeable biological product if the prescriber indicates that substitution is not authorized or if the patient expresses a desire not to receive an interchangeable product. The bill also outlines the communication requirements for pharmacists to notify prescribers about the dispensed product, which can be done through various electronic means or other methods if necessary. The effective date of the act is set for 60 days after its passage, with an approval date of July 15, 2025.

Statutes affected:
Introduced: 318:47-dd
As Amended by the Senate: 318:47-dd
Version adopted by both bodies: 318:47-dd
CHAPTERED FINAL VERSION: 318:47-dd